Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 23Recruiting 19Active not recruiting 17Terminated 16Withdrawn 4Unknown 4Not yet recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Specimen Handling 31Magnetic Resonance Spectroscopy 19Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Surgical Procedures, Operative 5Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × encorafenib × Clear all
NCT06102902 2026-05-13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡